Filter Releases
 
News Releases
Date Title and Summary View
Jun 22, 2016
SAN DIEGO, June 22, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Mark Gergen will step down as Executive Vice President and Chief Operations Officer to pursue other opportunities, transitioning over the coming months.       "We want to thank Mark for his important contributions and leadership over the p...
Jun 5, 2016
SAN DIEGO, June 5, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today provided an update on three current ongoing clinical programs in patients with non-small cell lung cancer (NSCLC) and other solid tumors. "We are making significant progress in the development of our pipeline as our ongoing clinical programs are showing m...
Jun 1, 2016
SAN DIEGO, June 1, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 11:00 a.m. ET (8:00 a.m. PT) in New York. A live audio webcast of the pres...
May 19, 2016
SAN DIEGO, May 19, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that abstracts on its investigational tyrosine kinase inhibitor candidates, glesatinib (MGCD265) and sitravatinib (MGCD516), will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL from June 3-...
May 5, 2016
SAN DIEGO, May 5, 2016 /PRNewswire/ --Mirati Therapeutics, Inc. (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2016 and provided an update on its product development programs. "We are encouraged by the progress made so far this year in advancing our three clinical stage oncology drug candidates, which ...
Mar 24, 2016
SAN DIEGO, March 24, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced it will present preclinical data on two of its three oncology therapies currently in development. Data on glesatinib (MGCD265), its tyrosine kinase inhibitor targeting MET and Axl; and mocetinostat (MGCD103), its spectrum-selective HDAC inhibitor, wil...
Mar 23, 2016
SAN DIEGO, March 23, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016. Mr. Donadio first joined Mirati in 2013 serving as Vice President of Finance. In his new role, he will be responsible for a...
Mar 9, 2016
SAN DIEGO, March 9, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided an update on its drug development programs. "We made significant progress across our entire pipeline in 2015, setting up a potentially transformative year...
Mar 8, 2016
SAN DIEGO, March 8, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016 at 2:05 p.m. ET (11:05 a.m. PT) in Miami. A live audio webcast of the prese...
Jan 8, 2016
SAN DIEGO, Jan. 8, 2016 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Marcy Graham has been appointed Vice President, Investor Relations (IR) and Corporate Communications. As a seasoned communicator, Ms. Graham has more than 15 years of experience in the biopharmaceutical sector with expertise in growth companies and...
Dec 21, 2015
REDWOOD CITY, Calif. and SAN DIEGO, Dec. 21, 2015 /PRNewswire/ -- Guardant Health, the market leader in liquid biopsies, and Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, announced today that they have entered into a collaboration for the development of a circu...
Dec 21, 2015
CAMBRIDGE, Mass. and SAN DIEGO, Dec. 21, 2015 /PRNewswire/ -- Foundation Medicine, Inc. (NASDAQ: FMI) and Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, today announced that they have entered into a collaboration for the development of a companion diagnostic tes...
Dec 21, 2015
SAN DIEGO, Dec. 21, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265. Glesatinib is an inhibitor of the MET and Axl receptor tyrosine kinase pathways which, when al...
Dec 17, 2015
SAN DIEGO, Dec. 17, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD516. The trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways, RET, DDR and Trk, w...
Dec 1, 2015
SAN DIEGO, Dec.1, 2015 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) will be presenting at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m. ET (6:45 a.m. PT) in New York. Charles M. Baum, M.D., Ph.D., president and CEO of Mirati, will provide a corporate overview. A live audio ...
= add release to Briefcase